Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus carboplatin and etoposide in elderly extensive-stage small-cell lung cancer (LOGIK2003 Turtle)
jRCTs071210050Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Primary endpoint: Safety. Started Aug 2021; status: completed.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCTs071210050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210050.